Just as athletes and actors go all-out in scrimmages and dress rehearsals before an actual game or performance, surgeons can now fully immerse themselves in a surgical procedure before they set foot in the operating room.

Temperature-control technology maker Ember’s business runs hot and cold—literally.

The chemo cocktail known as folfirinox is the go-to treatment for pancreatic cancer, but it works in only about 30% of patients, and those responders eventually relapse. Scientists at Washington University School of Medicine in St. Louis set out to find a way to make pancreatic cancer more amenable to chemo—and they found it in an unexpected place.

The humble mammogram may soon be getting a complementary new partner to boost breast cancer screening.

Insilico Medicine launched its first trial in humans of its computer-designed drug candidate after demonstrating its artificial intelligence platforms could not only identify a potentially new cellular target for the treatment of idiopathic pulmonary fibrosis but also conjure up a novel drug in less than 18 months and for pennies-on-the-dollar compared to most Big Pharma R&D efforts.

Rachelle Doody, M.D., Ph.D., was 25 years into her career in academia as a neurologist, constantly fighting to keep things the same as a chair of the Center for Alzheimer’s and Neurodegenerative Diseases at the Baylor College of Medicine.

Sanofi is adding another thread to its mRNA strategy. Having already bagged Translate Bio’s mRNA platform, Sanofi is now snapping up Origimm Biotechnology to land a therapeutic acne vaccine it plans to pair with the red-hot technology.

Portable MRI machine maker Hyperfine obtained a new clearance from the FDA, adding deep-learning algorithms that can boost the quality of images taken by its scanner-on-wheels.

Back when Brandy Matthews, M.D., was seeing Alzheimer’s disease patients as a behavioral neurologist, she found the most important thing she could offer was information.

The FDA still hasn’t found what its looking for in TG Therapeutics’ application for the leukemia and lymphoma combo treatment nicknamed U2, and so the therapy will be examined at an advisory committee meeting.